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s COPD Control a Useful Concept? Assessing
reatment Success by Evaluating COPD-Related
ealth Status
Es útil el concepto de control de la EPOC?: evaluación del éxito
erapéutico a partir de la valoración del estado de salud en
elación con la EPOC
o the Editor,
In most chronic diseases, treatment decisions are usually based
n whether control has been achieved in a given patient. This
oncept can have some clinical utility in COPD. However, there is
urrently no deﬁnition of well-controlled disease, and no objective
riteria to deﬁne control in COPD or any objective tools to measure
t.1 In fact, it is still unclear how to evaluate response to treatment
n COPD.2
In asthma, control is an important concept, because severity is
ssessed retrospectively from the level of treatment required to
ontrol the disease.3 However, in asthma, the concept of control
s easily confused with the concept of severity, as they repre-
ent overlapping dimensions.4 This is not the case in COPD, and
OLD 2016, unlike previous versions, recommends using the Clini-
al COPD Questionnaire5,6 in addition to CAT and/or mMRC as a tool
or evaluating symptoms and assessing COPD health status, not as
 direct measure of COPD control.7
Patients with COPD seek health care mostly due to exertio-
al dyspnoea and limitation of physical activity: breathlessness
s the most common symptom limiting exercise capacity, and
xercise intolerance or decreased physical activity are present
rom the beginning of the disease.8 The degree of physical acti-
ity is the best predictor of all-cause mortality,9 and COPD can
e understood as an exercise intolerance disease that can impact
aily activities. From the patient’s point of view, there should be
everal therapeutic successes in COPD, given the different per-
eptions of dyspnoea, variability in physical activity and general
ell-being.
COPD is characterised by persistent airway limitation that is
sually progressive and not fully reversible. The term COPD brings
ogether a number of entities with different clinical and pat-
ophysiological features, and the treatment goals are symptomatic
mprovement, prevention of exacerbations and disease progres-
ion. The high mortality associated with COPD is mainly due to
xacerbations requiring hospitalisation. Acute exacerbations also
ontribute to worsening of pulmonary function, change the trajec-
ory of the disease, and contribute to impairment of health-related
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deﬁne in COPD. However, based on the deﬁnition of the disease
and the goals of treatment, there are probably two  main domains in
COPD control: a functional domain, focussed on FEV1, and a clinical
domain, focussed on exacerbations.
Nevertheless, the therapeutic deﬁnition of success should not
only be based on control as a biomedical concept, but rather on a
multidimensional dimension, a general COPD-related health status,
that should incorporate the patient’s perspective, considering also
the “quality of life” dimension.
As control of symptoms is insufﬁcient to control the disease and
its progression, the patient has a limited capacity to deﬁne thera-
peutic success in order to participate in clinical decision-making:
control is thus a limiting biomedical concept. To deﬁne therapeu-
tic success, therefore, we  also need to take in account the idea of
patient well-being.
COPD is a chronic and incurable disease, and although it is unli-
kely that most patients will remain asymptomatic, their symptoms
improve with continuous bronchodilator use. The best possible
improvement in symptoms and lung function, and the absence of
exacerbations, seems to be more similar to the notion of contro-
lled disease, but it is certainly part of therapeutic success. The idea
of therapeutic success is useful, because it is linked to the con-
cept of value.10 Value in medicine must be deﬁned in terms of the
patient: it is the patient’s health outcomes that matter. In clinical
practice, however, it is important to deﬁne and manage the deter-
minant factors of therapeutic success in COPD. There is a need to
personalise treatment strategies,11 and four goals must be achie-
ved. First, we  have to assess the patient in a multidimensional way,
according to the severity of the disease, its activity, future risk and
impact on the patient, including their well-being. This allows us
to deﬁne treatable clinical characteristics and assess future risk,
and helps us tailor treatments to individual patients.12,13 Second,
we have to evaluate the patient’s perspectives and beliefs about
the treatment and the disease.14 Third, it is important to pres-
cribe the correct treatment, based on the best medical evidence,
taking in account pulmonary and extra pulmonary factors, the
patient’s perspective and their behaviours/lifestyle. And fourth,
we should monitor the treatment, assess and improve adherence,
ensure correct inhalation technique and monitor the patient’s
well-being.
Rather than assessing treatment success based merely on the
level of control that has been achieved, we  should move to a more
comprehensive concept by assessing COPD-related health status
and evaluating the changes or the maintenance of a certain level of
quality of life based on pre-established treatment goals. Deciding
which tool or set of tools to use is another matter and should be
discussed in another paper.15Conﬂicts of Interest
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